Johnson & Johnson published its 2025 annual report, outlining increased focus on six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. The company reported 5% operational sales growth in 2025 and noted that growth excluding STELARA was 12%. It said it invested more than USD 32 billion in research, development and strategic acquisitions, including Intra-Cellular Therapies and Halda Therapeutics. In MedTech, it cited continued adoption of its VARIPULSE platform, used to treat over 40,000 atrial fibrillation patients, and said it filed an FDA de novo submission for its OTTAVA robotic surgery system. Johnson & Johnson also announced plans to separate its Orthopaedics business, targeting completion within 18 to 24 months of the initial announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on March 11, 2026, and is solely responsible for the information contained therein.